SBP target of lower than 120 mmHg reduces CV events in T2DM

Shawna Nesbitt

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

AHA exists 100 years: What can we possibly expect in the next century?
AHA exists 100 years: What can we possibly expect in the next century?
AHA 2024
AHA exists 100 years: What can we possibly expect in the next century?
- Keith Churchwell, MD
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
AHA 2024
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
AHA 2024
No benefit of routine spironolactone post-MI
- Sanjit Jolly, MD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA